MAFFEZZOLI, MICHELE
 Distribuzione geografica
Continente #
EU - Europa 160
NA - Nord America 103
AS - Asia 80
AF - Africa 7
Totale 350
Nazione #
US - Stati Uniti d'America 102
IT - Italia 89
SG - Singapore 51
CN - Cina 23
IE - Irlanda 23
FR - Francia 21
DE - Germania 12
MA - Marocco 6
SE - Svezia 5
IN - India 4
NL - Olanda 3
AT - Austria 2
FI - Finlandia 2
PH - Filippine 2
BE - Belgio 1
CA - Canada 1
CI - Costa d'Avorio 1
ES - Italia 1
RU - Federazione Russa 1
Totale 350
Città #
Singapore 43
Dublin 23
Boardman 20
Santa Clara 19
Ashburn 15
Marseille 15
Milan 15
Parma 13
Shanghai 12
Modena 11
Beijing 6
Meknes 6
Munich 6
Paris 6
Bologna 5
Aachen 3
Brescia 3
Scandiano 3
Busto Arsizio 2
Felino 2
Jerago Con Orago 2
Los Angeles 2
Pune 2
Sant'Ambrogio di Valpolicella 2
Venice 2
Vienna 2
Abidjan 1
Ancona 1
Brussels 1
Castel di Lama 1
Chennai 1
Chicago 1
Cologno Monzese 1
Desio 1
Helsinki 1
Ivrea 1
Kolkata 1
Leipzig 1
Magdeburg 1
Montecassiano 1
Moscow 1
Newark 1
Nuremberg 1
Ottawa 1
Padova 1
Quezon City 1
Rome 1
Seattle 1
Soliera 1
Totale 263
Nome #
Real world analysis of peritoneal metastasis from renal cell carcinoma: Meet-Uro 27 study 45
Takotsubo syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab plus axitinib 42
91 Circulating lipid profile as a prognostic factor in patients with advanced solid tumors treated with immune checkpoint inhibitors 37
Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario 32
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study 29
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors 22
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study) 19
Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27 17
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors 15
Prognostication for surgically treated papillary renal cell carcinoma: which model is the optimal choice? 14
External validation of the GRade, Age, Nodes and Tumor (GRANT) score for patients with surgically treated papillary renal cell carcinoma. - Proceedings from the Second International Urology Cancer Summit, 27th September, Portsmouth, UK. 14
Use of concomitant proton pump inhibitors, statins, or metformin in patients treated with pembrolizumab for advanced urothelial carcinoma: data from the ARON-2 retrospective study. 13
Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study 13
Prognostic models for patients with metastatic urothelial carcinoma: why to use them? 13
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations 13
Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy 12
Immunohistochemical (IHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: secondary analyses of the Meet-URO 18 study 11
The distinct prognostic impact of circulating lipid profile according to neutrophil to lymphocyte ratio in patients with advanced solid tumors treated with immune check point inhibitors. 8
Totale 369
Categoria #
all - tutte 2.289
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.289


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202361 0 0 0 0 11 2 5 1 27 0 15 0
2023/2024121 0 8 4 3 14 13 13 9 16 9 15 17
2024/2025187 7 36 44 35 65 0 0 0 0 0 0 0
Totale 369